- Leadership team expanded with appointment of Kathy Reape, M.D. as chief development officer - AK-OTOF granted both Orphan Drug Designation and Rare Pediatric Disease Designation by FDA and is on track for planned IND submission in first half of 2022 - Nonclinical data supporting future clinical

- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficient for sustained restoration of auditory function in Otof knockout mice - Multiple analyses

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Dr. Kathy Reape as chief development officer.

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder,

BOSTON, April 27, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that new nonclinical data will be presented at the American

BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the U.S. Food and Drug Administration (FDA) has granted

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., founder, president, and

- In 2020, continued to advance genetic medicine pipeline with execution of IND-enabling studies for AK-OTOF and general alignment with FDA on the path to a 2022 IND submission for AK-antiVEGF - Raised approximately $349 million in gross proceeds, which is expected to fund operations for at least

The Resonate™ program provides access to a potential genetic diagnosis by offering genetic testing at no cost to eligible individuals, their insurance, or their healthcare providers A genetic diagnosis may help individuals and their healthcare providers better understand an individual’s condition